Please login to the form below

Not currently logged in
Email:
Password:

Crestor fails to outshine Lipitor

AstraZeneca's cholesterol drug Crestor has failed to show an advantage over its rival Lipitor in study data released by the pharmaceutical company

AstraZeneca's (AZ) cholesterol drug Crestor (rosuvastatin) has failed to show an advantage over its rival Lipitor (atorvastatin) in top-line study data released by the pharmaceutical company.

Results for the study's primary measure of efficacy, involving the amount of fat in a patient's arteries, demonstrated no statistically significant difference between the two treatments.

These results have the potential to damage Crestor's sales once Lipitor loses its patent protection later this year and is opened to generic completion, with healthcare providers more likely to opt for the cheaper option of two similar performing treatments.

The trial involved around 1,300 patients with coronary artery disease over a 104-week period.

Despite the failure of the primary endpoint to indicate success for Crestor, a secondary endpoint that involved an alternative process to the way fat was measured in the artery, did demonstrate a statistically significant reduction in fat build-up compared with Lipitor.

Further data and analyses will be presented by the study's academic investigators at the American Heart Association Scientific Sessions (AHA) on November 15.

5th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
StratX

StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics